This report brief assess the global public health implications of falsified, substandard, and counterfeit pharmaceuticals in an attempt to help jumpstart international discourse about this problem. In addition it lays out a plan to invest in quality medications to improve public health outcomes and eliminate the burden of falsified and substandard medicines.
Countering the Problem of Falsified and Substandard Drugs, February 2013
